Blog
RSS FeedPosted by Michael Wonder on 09 Nov 2023
Getting ready for EMA’s website relaunch on 5 December 2023
9 November 2023 - The EMA is relaunching its corporate website on 5 December 2023. ...
Posted by Michael Wonder on 09 Nov 2023
UnitedHealth unit to add eight insulin products to its reimbursement list
9 November 2023 - UnitedHealth's pharmacy benefit manager unit said on Thursday it was adding eight insulin products to its ...
Posted by Michael Wonder on 09 Nov 2023
FDA amends pembrolizumab’s gastric cancer indication
9 November 2023 - On 7 November 2023, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine, ...
Posted by Michael Wonder on 09 Nov 2023
MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss
8 November 2023 - For the first time in the UK, obese patients and people who are overweight with weight-related health ...
Posted by Michael Wonder on 09 Nov 2023
Vanflyta approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML
9 November 2023 - Approval based on QuANTUM-First results demonstrating Vanflyta added to chemotherapy improved overall survival. ...
Posted by Michael Wonder on 09 Nov 2023
Same drug, two prices: why the higher price prevails
8 November 2023 - Patients are paying hundreds of dollars more for a prescription than they would if their health plan ...
Posted by Michael Wonder on 09 Nov 2023
HHS considers removing J&J’s Stelara from Medicare drug price negotiations
7 November 2023 - The Department of Health and Human Services in a supplemental court filing posted late last week ...
Posted by Michael Wonder on 09 Nov 2023
FDA’s Califf wants to get the public as excited about life expectancy as cures
8 November 2023 - It’s easy to get people worked up about cures, but they don’t seem to be bothered ...
Posted by Michael Wonder on 09 Nov 2023
Takeda receives US FDA approval of Fruzaqla (fruquintinib) for previously treated metastatic colorectal cancer
8 November 2023 - Fruzaqla is the first targeted therapy approved for metastatic colorectal cancer regardless of biomarker status or ...
Posted by Michael Wonder on 09 Nov 2023
PHARMAC asked to reconsider funding RSV drug for at risk babies
9 November 2023 - Paediatricians and neonatal experts are pleading with PHARMAC to rethink its decision to stop funding a ...
Posted by Michael Wonder on 09 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (9 November 2023)
9 November 2023 - Two more documents are now available. ...
Posted by Michael Wonder on 08 Nov 2023
First electronic product information published for selected human medicines
8 November 2023 - The Heads of Medicines Agencies (HMA), the European Commission and EMA have published for the first time ...
Posted by Michael Wonder on 08 Nov 2023
Samsung Bioepis & Organon announce FDA acceptance of supplemental biologics license application for interchangeability designation for Hadlima (adalimumab-bwwd), a biosimilar to Humira
7 November 2023 - Supplemental biologics license application based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: ...
Posted by Michael Wonder on 08 Nov 2023
FDA approves new medication for chronic weight management
8 November 2023 - Today, the US FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body ...
Posted by Michael Wonder on 08 Nov 2023
Biogen-Sage Therapeutics post partum depression pill priced at $15,900
7 November 2023 - Sage Therapeutics has priced the oral post partum depression pill it developed with partner Biogen at ...